AWM
KRYS icon

Avior Wealth Management’s Krystal Biotech KRYS Stock Holding History

Avior Wealth Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-26
Closed -$4.07K – 1615
2024
Q4 		$4.07K Sell
26
-8
-24% -$1.42K ﹤0.01% 1929
2024
Q3 		$6.19K Hold
34
– – ﹤0.01% 1704
2024
Q2 		$6.24K Sell
34
-9
-21% -$1.51K ﹤0.01% 1660
2024
Q1 		$7.65K Buy
+43
New +$5.97K ﹤0.01% 1954

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Avior Wealth Management's KRYS Position: Q1 2025 in Review

Avior Wealth Management sold out of Krystal Biotech (KRYS) in Q1 2025, closing a stake of 26 shares — an estimated $4.07K sold.

Avior Wealth Management first reported a position in KRYS in Q1 2024 and held it in 4 quarters. The position peaked at $7.65K in Q1 2024. 299 funds tracked by Wall St. Rank hold KRYS as of Q1 2025.

  • Avior Wealth Management reported no remaining Krystal Biotech position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 26 Krystal Biotech shares in Q1 2025, an estimated $4.07K.
  • Avior Wealth Management first reported a position in Krystal Biotech in Q1 2024 and held it in 4 quarters.
  • Avior Wealth Management's Krystal Biotech position peaked at $7.65K in Q1 2024.
  • 299 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.